Michelle Segovia

Appearances

PREGNANCY OUTCOMES AFTER MATERNAL OR PATERNAL EXPOSURE IN THE TOFACITINIB ULCERATIVE COLITIS CLINICAL PROGRAM
Date
May 20, 2024
BACKGROUND: Pregnant women with ulcerative colitis (UC) have a higher risk of adverse pregnancy outcomes vs age-matched controls.1 Tofacitinib is an oral Janus kinase inhibitor for the treatment of UC. There are no well-controlled studies on tofacitinib use in pregnant women…
Presenter
Uma Mahadevan
University of California san francisco
Speakers
María Chaparro
Michelle Segovia
Nicole Kulisek
Xiang Guo
Joseph Wu
Ivana Vranic
Annette Diehl
Marla Dubinsky
Icahn School of Medicine, Mount Sinai